Short-Acting Insulin Market to Surge on Personalized Therapy Demand The Short-Acting Insulin Market encompasses a range of insulin analogs and formulations designed for rapid glycemic control in patients with type 1 and type 2 diabetes. These products, including regular human insulin and fast-acting analogs, offer precise dosage delivery, reduced hypoglycemia risk and improved postprandial blood glucose management. Short-Acting Insulin Market growing prevalence of diabetes, rising awareness of tight glycemic targets and the shift toward patient-centric treatment regimens have driven demand for short-acting insulin. Benefits such as ease of dose titration, compatibility with insulin pumps and convenience of co-formulation with delivery devices meet clinicians’ requirements for flexible management protocols. Advances in formulation chemistry and delivery technology are enhancing absorption profiles and stability, addressing key challenges in insulin therapy. As healthcare systems emphasize cost-effective interventions to reduce long-term complications, the need for reliable, fast-acting insulin options intensifies. The short-acting insulin market is estimated to be valued at USD 10.00 Bn in 2025 and is expected to reach USD 14.35 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032. Short-Acting Insulin Market: https://www.coherentmi.com/industry-reports/short-acting-insulin-market